These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24236974)

  • 21. Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders.
    Parenti G; Andria G; Valenzano KJ
    Mol Ther; 2015 Jul; 23(7):1138-1148. PubMed ID: 25881001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Second-Generation Pharmacological Chaperones: Beyond Inhibitors.
    Tran ML; Génisson Y; Ballereau S; Dehoux C
    Molecules; 2020 Jul; 25(14):. PubMed ID: 32660097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease.
    Lukas J; Knospe AM; Seemann S; Citro V; Cubellis MV; Rolfs A
    J Vis Exp; 2017 Dec; (130):. PubMed ID: 29286471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacological chaperones: a potential therapeutic treatment for conformational diseases].
    Mendre C; Mouillac B
    Med Sci (Paris); 2010; 26(6-7):627-35. PubMed ID: 20619166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacoperone drugs: targeting misfolded proteins causing lysosomal storage-, ion channels-, and G protein-coupled receptors-associated conformational disorders.
    Hou ZS; Ulloa-Aguirre A; Tao YX
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):611-624. PubMed ID: 29851355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies.
    Germain DP; Fan JQ
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S111-7. PubMed ID: 20040321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants.
    Sawkar AR; Schmitz M; Zimmer KP; Reczek D; Edmunds T; Balch WE; Kelly JW
    ACS Chem Biol; 2006 May; 1(4):235-51. PubMed ID: 17163678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chaperone therapy for molecular pathology in lysosomal diseases.
    Suzuki Y
    Brain Dev; 2021 Jan; 43(1):45-54. PubMed ID: 32736903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A chaperone-mediated approach to enzyme enhancement as a therapeutic option for the lysosomal storage disorders.
    Pastores GM; Sathe S
    Drugs R D; 2006; 7(6):339-48. PubMed ID: 17073517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological Chaperones: A Therapeutic Approach for Diseases Caused by Destabilizing Missense Mutations.
    Liguori L; Monticelli M; Allocca M; Hay Mele B; Lukas J; Cubellis MV; Andreotti G
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31940970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment options for lysosomal storage disorders: developing insights.
    van Gelder CM; Vollebregt AA; Plug I; van der Ploeg AT; Reuser AJ
    Expert Opin Pharmacother; 2012 Nov; 13(16):2281-99. PubMed ID: 23009070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New strategies for the treatment of lysosomal storage diseases (review).
    Parenti G; Pignata C; Vajro P; Salerno M
    Int J Mol Med; 2013 Jan; 31(1):11-20. PubMed ID: 23165354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nonyl)deoxynojirimycin.
    Luan Z; Higaki K; Aguilar-Moncayo M; Ninomiya H; Ohno K; García-Moreno MI; Ortiz Mellet C; García Fernández JM; Suzuki Y
    Chembiochem; 2009 Nov; 10(17):2780-92. PubMed ID: 19830760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological chaperones: potential treatment for conformational diseases.
    Bernier V; Lagacé M; Bichet DG; Bouvier M
    Trends Endocrinol Metab; 2004 Jul; 15(5):222-8. PubMed ID: 15223052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological Chaperones: Design and Development of New Therapeutic Strategies for the Treatment of Conformational Diseases.
    Convertino M; Das J; Dokholyan NV
    ACS Chem Biol; 2016 Jun; 11(6):1471-89. PubMed ID: 27097127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapy for lysosomal storage disorders.
    Beck M
    IUBMB Life; 2010 Jan; 62(1):33-40. PubMed ID: 20014233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The world of galactose and glucose: pathogenesis and therapy of lysosomal diseases].
    Suzuki Y
    No To Hattatsu; 2014 Mar; 46(2):81-6. PubMed ID: 24738180
    [No Abstract]   [Full Text] [Related]  

  • 38. Enzyme replacement therapy for lysosomal storage diseases.
    Ohashi T
    Pediatr Endocrinol Rev; 2012 Oct; 10 Suppl 1():26-34. PubMed ID: 23330243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacotherapeutic strategies using small molecules for the treatment of glycolipid lysosomal storage disorders.
    Butters TD
    Expert Opin Pharmacother; 2007 Mar; 8(4):427-35. PubMed ID: 17309337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatments for lysosomal storage disorders.
    Lachmann R
    Biochem Soc Trans; 2010 Dec; 38(6):1465-8. PubMed ID: 21118108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.